Structure-Based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening
Authors:
- 21 November 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Combinatorial Chemistry
- Vol. 9 (1) , 131-138
Abstract
3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate. In many classes of organisms, this is the committed step leading to the synthesis of essential compounds, such as cholesterol. However, a high level of cholesterol is an important risk factor for coronary heart disease, for which an effective clinical treatment is to block HMGR using inhibitors like statins. Recently the structures of catalytic portion of human HMGR complexed with six different statins have been determined by a delicate crystallography study (Istvan and Deisenhofer Science 2001, 292, 1160−1164), which established a solid basis of structure and mechanism for the rational design, optimization, and development of even better HMGR inhibitors. In this study, three-dimensional quantitative structure−activity relationship (3D QSAR) with comparative molecular field analysis (CoMFA) was performed on a training set of up to 35 statins and statin-like compounds. Predictive models were established by using two different ways: (1) Models-fit, obtained by SYBYL conventional fit-atom molecular alignment rule, has cross-validated coefficients (q2) up to 0.652 and regression coefficients (r2) up to 0.977. (2) Models-dock, obtained by FlexE by docking compounds into the HMGR active site, has cross-validated coefficients (q2) up to 0.731 and regression coefficients (r2) up to 0.947. These models were further validated by an external testing set of 12 statins and statin-like compounds. Integrated with CoMFA 3D QSAR predictive models, molecular surface property (electrostatic and steric) mapping and structure-based (both ligand and receptor) virtual screening have been employed to explore potential novel hits for the HMGR inhibitors. A representative set of eight new compounds of non-statin-like structures but with high pIC50 values were sorted out in the present study.Keywords
This publication has 19 references indexed in Scilit:
- Efficient Generation, Storage, and Manipulation of Fully Flexible Pharmacophore Multiplets and Their Use in 3-D Similarity SearchingJournal of Chemical Information and Computer Sciences, 2003
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001
- Crystal structure of the catalytic portion of human HMG‐CoA reductase: insights into regulation of activity and catalysisThe EMBO Journal, 2000
- Evaluation of the FLEXX incremental construction algorithm for protein-ligand dockingProteins: Structure, Function, and Bioinformatics, 1999
- Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitorsJournal of Medicinal Chemistry, 1993
- Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of 3-hydroxy-3-methylglutarate-CoA reductase inhibitorsJournal of Medicinal Chemistry, 1993
- Regulation of the mevalonate pathwayNature, 1990
- Validation of the general purpose tripos 5.2 force fieldJournal of Computational Chemistry, 1989
- Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteinsJournal of the American Chemical Society, 1988
- Iterative partial equalization of orbital electronegativity—a rapid access to atomic chargesTetrahedron, 1980